{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:56:28Z","timestamp":1790837788236,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Schizophrenia is a chronic and heterogeneous psychiatric disorder characterized\nby positive and negative symptoms, together with cognitive dysfunction. Because current\nantipsychotic-based treatment remains limited for negative and cognitive symptoms, adjunctive\nstrategies targeting additional pathophysiological pathways are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This narrative review synthesized preclinical and clinical evidence on selected medicinal\nplants, standardized extracts and plant-derived bioactive compounds investigated as adjunctive approaches\nin schizophrenia. Evidence was organized according to plant source or compound, putative\nmechanisms of action, preclinical findings, clinical evidence, symptom domains, antipsychoticassociated\nadverse effects and pharmacological pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The reviewed interventions targeted oxidative stress, neuroinflammation, glutamatergic and\ndopaminergic dysfunction, endocannabinoid modulation, mitochondrial function and neurotrophic\nsignaling. Randomized clinical evidence was available for a limited subset of candidates, including\ncannabidiol, Withania somnifera, L-theanine, curcumin-based formulations, Ginkgo biloba and\nPanax quinquefolius. Most other agents remained supported mainly by preclinical, mechanistic or\nindirect clinical evidence. Potential benefits included improvement in positive, negative or cognitive\nsymptom domains and attenuation of selected antipsychotic-associated adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The evidence base remains heterogeneous, with substantial variation in formulations,\ndoses, treatment duration, outcome measures and translational maturity. Bioavailability and standardization\nare major challenges for several compounds, particularly polyphenols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Plant-based interventions should be positioned as adjunctive, not alternative, approaches.\nFurther adequately powered clinical trials using standardized preparations are required to clarify\nefficacy, safety, optimal dosing and clinical relevance in schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501514494260916073129","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:11:03Z","timestamp":1790835063000},"source":"Crossref","is-referenced-by-count":0,"title":["Plant-derived Bioactive Compounds in Schizophrenia: Pharmacological\nMechanisms and Emerging Drug Targets"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2329-7298","authenticated-orcid":true,"given":"Marta Raquel Costa","family":"Loureiro","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2030-0057","authenticated-orcid":true,"given":"Jo\u00e3o Paulo","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Directorate of Risk Management of Medicines,INFARMED - National Authority of Medicines and Health Products, I.P., Lisbon, Portugal"},{"name":"Faculty of Pharmacy,University of Lisbon, Lisbon, Portugal"},{"name":"Laboratory of Systems Integration Pharmacology, Clinical and RegulatoryScience, Research Institute for Medicines of the University of Lisbon (iMED.ULisboa), Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-3612","authenticated-orcid":true,"given":"Ant\u00f3nio","family":"Paranhos","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501514494260916073129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258903\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501514494260916073129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:11:10Z","timestamp":1790835070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258903\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501514494260916073129","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}